CXCR4 and lymphoma: These nanoparticles effectively promoted tumor cell death in vitro and potent CXCR4-dependent anti-tumor effects without systemic toxicity in CXCR4+ tumor mouse models of lymphoma [108,110], colorectal [111], endometrial cancer [109], and acute myeloid leukemia [112].